Leading a renaissance in kidney disease treatment


Goldfinch Bio is a biotechnology company that is singularly focused on discovering and developing precision therapies for patients with kidney disease. Just as the goldfinch has long been a symbol of healing and renewal and was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for people with kidney disease.


Year Invested: 2016
Location: Cambridge, Mass.
Visit: www.goldfinchbio.com

Recent News

October 29, 2018
Goldfinch Bio Announces GFB-887 As Clinical Development Candidate And Presents Data Demonstrating Selective Inhibition Of TRPC5 For The Treatment Of Genetically-Driven Kidney Disease

October 5, 2018
Goldfinch Bio to Present Data on Trpc5 Inhibitor for Proteinuric Kidney Disease and Its Kidney Genome Atlas for Identification of Novel Targets

May 31, 2018
Goldfinch Bio Presents Data on TRPC5 Inhibition as a Target for Proteinuric Kidney Disease and Announces GFB-887 as Lead Drug Program to treat FSGS

Read More News

Associated Team Members

Philip Reilly, M.D., J.D.
Venture Partner

Neil Exter
Partner

Abbie Celniker, Ph.D.
Partner

Eric Green, M.D., Ph.D.
Entrepreneur-in-Residence

Walter Kowtoniuk, Ph.D.
Principal